Gosset Ownership
Private
Employees
~3
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Bird Rock Bio General Information
Bird Rock Bio completed a Phase 1b multiple ascending dose trial for nimacimab in patients with non-alcoholic fatty liver disease (NAFLD) and diabetes or pre-diabetes. The trial showed no serious adverse events or early terminations due to adverse events. The company's lead candidate gerilimzumab (anti-IL-6 antibody) demonstrated safety and pharmacokinetics supporting low, infrequent dosing in clinical trials.
Contact Information
Primary Industry
Biotech
Corporate Office
La Jolla, California
United States
United States
Drug Pipeline
namacizumab
Phase 2Key Partnerships
Janssen Pharmaceuticals, Inc., GE Healthcare, argenx, Genor Biopharma
Bird Rock Bio Funding
No funding data available
To view Bird Rock Bio's complete valuation and funding history, request access »